GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
A sovereign can never abdicate. He can be deposed... All right. That is force. But abdicate – never, never, never! I would rather fall here at your side. Then there would be Otto. And even if all of us here were killed, there would still be other Habsburgs! Charles gave his permission for the document to be published, and he, his family and the remnants of his Court departed for the Royal shooting lodge at Eckartsau, close to the borders with Hungary and Slovakia. The Republic of German-Austria was proclaimed the next day.
== History and etymology == In 1840-1841, Carl Julius Fritzsche was able to extract and crystallize two acids from the products of reaction of indigo dye with caustic potash, which he called chrysanilic and anthranilic acids after their colors before purification (golden yellow and black respectively) and the plant anil (Indigofera suffruticosa). The former was identified as ortho-carboxy anil of indoxyl-2-aldehyde only in 1910 while the latter was identified as salicylamide already in 1843 by Cahours.
=== Introns can be mobile genetic elements === Some self-splicing introns can spread through a population of organisms by "homing", inserting copies of themselves into genes at sites that previously lacked an intron. Because they are self-splicing (that is, they remove themselves at the RNA level from genes into which they have inserted), these sequences represent transposons that are genetically silent, i.e. they do not interfere with the expression of the gene into which they become inserted. These introns can be regarded as examples of selfish DNA. Some mobile introns encode homing endonucleases, enzymes that initiate the homing process by specifically cleaving double-stranded DNA at or near the intron-insertion site of alleles lacking an intron. Mobile introns are frequently members of either the group I or group II families of self-splicing introns.
=== Campaigns === On November 8, 1980, Sanders announced his candidacy for mayor. He formally announced his campaign on December 16 at a City Hall press conference. Sanders selected Linda Niedweske as his campaign manager. The Citizens Party attempted to nominate Greg Guma for mayor, but Guma declined, saying it would be "difficult to run against another progressive candidate". Sanders had been convinced to run for the mayoralty by his close friend Richard Sugarman, an Orthodox Jewish professor of religious studies at the University of Vermont, who had shown him a ward-by-ward breakdown of the 1976 Vermont gubernatorial election, in which Sanders had run, that showed him receiving 12% of the vote in Burlington despite only getting 6% statewide. Sanders initially won the mayoral election by 22 votes against incumbent mayor Gordon Paquette, Richard Bove, and Joseph McGrath, but the margin was later reduced to 10 votes. Paquette did not contest the results of the recount. Paquette did not campaign or promote his candidacy since neither Sanders nor Bove was seen as a serious challenger. Sanders had not previously won an election. Paquette was also considered to have lost because he proposed an unpopular $0.65 per $100 raise in taxes that Sanders opposed. Sanders spent around $4,000 on his campaign. Sanders criticized the pro-development incumbent as an ally of prominent shopping center developer Antonio Pomerleau, while Paquette warned of ruin for Burlington if Sanders were elected.
DC's Stargirl, or simply Stargirl, is an American superhero television series created by Geoff Johns that premiered on streaming service DC Universe. It is based on the DC Comics superhero Courtney Whitmore, created by Johns and Lee Moder. The series follows high school student Courtney Whitmore who discovers the cosmic staff originally wielded by Starman and becomes the inspiration for a new generation of superheroes who become the new incarnation of the Justice Society of America. DC Universe ordered the series in July 2018. Brec Bassinger was cast as Courtney Whitmore that September, with additional castings for her family members, the Justice Society of America, and the Injustice Society of America through February 2019. Filming for the series began in March 2019 in the Atlanta metropolitan area. Stargirl premiered on DC Universe on May 18, 2020; the first season consists of 13 episodes and also aired the following day on the broadcast network The CW. The second season, subtitled Summer School premiered on August 10, 2021, exclusively on The CW. The third and final season, subtitled Frenemies premiered on August 31, 2022. Ahead of the series premiere, characters from the series were featured in a cameo during the Arrowverse crossover "Crisis on Infinite Earths" through archive footage. It established Stargirl as existing on a parallel Earth to the Arrowverse. The show has received critical acclaim.
Sources: en.wikipedia.org
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) (, commonly ) is a toxin that is the main active component of chili peppers and gives them their distinct pungent, "spicy" or "hot" taste. It is a potent irritant for mammals for which it produces a sensation of burning in any tissue with which it comes into contact. Capsaicin and several related amides (capsaicinoids) are produced as secondary metabolites by chili peppers, likely as deterrents against eating by mammals and against the growth of fungi. Pure capsaicin is a hydrophobic, highly pungent (i.e., spicy) crystalline solid.
MLSE and NBA had applied to register the Raptor's logo Raptors, a basketball with three diagonal claw gashes, for various goods and services. The Trademark Trial and Appeal Board dismissed Monster's claim. In March 2016, Monster filed a lawsuit to revoke the company trademark of Thunder Beast LLC of Washington, D.C., a small root beer brewery, insisting the use of "beast" in the company name encroached on Monster's trademark slogan, "Unleash the Beast". The owner of Thunder Beast, Stephen Norberg, was fighting Monster's lawsuit as of 2019. In August 2018, Monsta Pizza of Wendover in Buckinghamshire, United Kingdom, fought a claim brought by Monster Energy in the Intellectual Property Office. The claim was that the pizza firm could be mistaken for Monster Energy, leaving customers confused. The pizza firm won a landmark ruling against Monster Energy, when the court decided there would be no case of misrepresentation. In fact, Monster Energy loses many of their lawsuits; however, as with other cases of "trademark bullying", the main goal of the lawsuit seems to be bankrupting the opposition at which they are quite successful. Also in 2018, Monster Energy brought a lawsuit against Vital Pharmaceuticals Inc. (VPX), then producer of Bang Energy, a competitor of Monster Energy. The lawsuit alleged false advertising as well as theft of trade secrets. The matter concluded with a jury verdict in favor of Monster Energy.
==== Sniper killings ==== In February 2024, an American doctor returning from the Gaza Strip wrote an op-ed in the Los Angeles Times stating that she had witnessed children being deliberately targeted by Israeli snipers, writing, "On one occasion, a handful of children, all about ages 5 to 8, were carried to the emergency room by their parents. All had single sniper shots to the head... None of these children survived." A Canadian doctor returning from a week in Gaza stated she had seen crimes against humanity, including small children "dying of hunger, bombs, sniper shots." Israeli drone footage released in March 2024 showed Israeli snipers killing an unarmed boy in Jabalia. In April 2024, doctors said they were seeing "a steady stream of children, elderly people and others who were clearly not combatants with single bullet wounds to the head or chest." Dr. Mark Perlmutter, an American doctor working in Gaza, stated Israeli snipers were targeting children, stating, "No toddler gets shot twice by mistake by the 'world's best sniper.' And they're dead-center shots." In August 2024, an American doctor returning from Gaza stated, "We had kids shot in the chest and shot in the head – in other words, clearly deliberate, clearly targeted". In October 2024, The New York Times reported compiled testimony from 44 doctors, nurses, and paramedics who treated multiple cases of preteen children with gunshot wounds to the head or chest in Gaza.
Arsenic trioxide (ATO) (Latin: Arsenum trioxydatum) is used as a chemotherapeutic agent in the treatment of acute promyelocytic leukemia (APL). It was approved for medical use in the United States in 2000. Arsenic trioxide is also included on the World Health Organization's List of Essential Medicines. Despite its therapeutic use, arsenic trioxide is highly toxic and has historically caused numerous cases of acute and chronic arsenic poisoning. It is classified as an orphan drug and is marketed under the brand name Trisenox. When dissolved in water, it forms arsenous acid. Arsenic trioxide inhibits the proliferation of cancer cells and promotes their differentiation or apoptosis, although its precise mechanism of action remains incompletely understood. Because of its toxicity, arsenic has been used for centuries as a potent poison. Its anticancer properties were recognized in the 20th century, but early efforts to administer it orally were ineffective. Therapeutic benefits were observed only with intravenous administration, particularly in treating the rare cancer acute promyelocytic leukemia. Initially, arsenic trioxide was used to treat APL only after standard retinoid and chemotherapy regimens had failed. However, it is now commonly used as first-line therapy in combination with tretinoin (ATRA) for patients with non-high-risk APL, rather than solely as salvage therapy following relapse. The treatment is generally well tolerated and associated with relatively few side effects. Ongoing research is investigating additional therapeutic applications for this drug.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.